Ergomed (ERGO)

 

Latest News

Notice of Preliminary Results

RNS Number: 0086A Ergomed plc 21 March 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed plc Notice of Preliminary Results London, UK - 21 March 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or 'the Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, will ann...

Ergomed initiates study of Peprostat

Ergomed has announced the initiation of a phase IIb proof-of-concept study for Peprostat, a highly innovative treatment f...

Initiates Phase II Study of Topical PeproStat

RNS Number: 8672Z Ergomed plc 20 March 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed Initiates Phase II study of topical PeproStat in Intraoperative surgical haemostatis Headline data expected in Q1 2018 British company's invention for surgical bleeding advances in clinical development London, UK - 20 March 2017: Ergomed plc (LSE: ERGO) ...

Ergomed notes partner's successful financing round

Ergomed has noted that its co-development partner Modus Therapeutics has announced a successful financing round, rais...

All News

DateHeadlineSource
21-03-17Notice of Preliminary ResultsRNS
20-03-17Ergomed initiates study of PeprostatStockMarketWire
20-03-17Initiates Phase II Study of Topical PeproStatRNS
20-02-17Ergomed notes partner's successful financing roundStockMarketWire
20-02-17Modus Therapeutics Raises SEK 32 MillionRNS
06-02-17Broker Forecast - Numis issues a broker note on Ergomed PlcStockMarketWire
06-02-17Broker Forecast - Stifel issues a broker note on Ergomed PlcStockMarketWire
06-02-17Positive Phase II top-line results of LorediplonRNS
03-02-17Broker Forecast - N+1 Singer issues a broker note on Ergomed PlcStockMarketWire
31-01-17Completion of ZoptrexT Phase 3 Clinical TrialRNS
17-01-1725 momentum stocks for 2017Interactive Investor
17-01-17Ergomed revenues up 26%StockMarketWire
17-01-17Trading StatementRNS
01-12-16Ergomed CFO and general counsel granted optionsStockMarketWire
30-11-16Award of Options by CEO to CFO and General CounselRNS
29-11-16Acquisition of PharmInventRNS
21-11-16Ergomed chairman to step down StockMarketWire
21-11-16Proposed Board ChangesRNS
16-11-16Ergomed expands clinical study with Modus TherapeuticsStockMarketWire
16-11-16Research Update from Modus TherapeuticsRNS
15-11-16Holding(s) in CompanyRNS
07-11-16Broker Forecast - N+1 Singer issues a broker note on Ergomed PlcStockMarketWire
01-11-16Co-Development Agreement with Asarina ABRNS
24-10-16Ergomed notes Dilaforette's plans for IPO StockMarketWire
24-10-16Ergomed notes news from co-development partnerRNS
21-10-16Broker Forecast - N+1 Singer issues a broker note on Ergomed PlcStockMarketWire
14-10-16Fourth licensing agreement for ZoptrexRNS
26-09-16Ergomed revenues up StockMarketWire
26-09-16Half-year ReportRNS
22-09-16Ergomed contract win StockMarketWire
22-09-16Contract win validates rationale of acquisitionsRNS
16-09-16Ergomed receives a "buy" recommendationRNS
08-09-16Ergomed completes clinical trial recruitment StockMarketWire
08-09-16Recruitment completed in phase IIa clinical trialRNS
07-09-16Notice of ResultsRNS
02-09-16Broker Forecast - Stifel issues a broker note on Ergomed PlcStockMarketWire
02-09-16Ergomed co-development partner licensing deals StockMarketWire
02-09-16Co-development partner announces licensing dealsRNS
15-08-16Change of Nominated AdviserRNS
15-08-16Disclosure of Directors' AppointmentsRNS

RSS feeds

  • Editorial news feed for LSE:ERGO Editorial
  • Regulatory news feed for LSE:ERGO Regulatory